Does the media prefer IDXX or ABT?

In the previous week, Abbott Laboratories had 47 more articles in the media than IDEXX Laboratories. MarketBeat recorded 49 mentions for Abbott Laboratories and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Abbott Laboratories' score of 1.10 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Abbott Laboratories 35 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer ISRG or IDXX?

In the previous week, Intuitive Surgical had 39 more articles in the media than IDEXX Laboratories. MarketBeat recorded 41 mentions for Intuitive Surgical and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Intuitive Surgical's score of 1.32 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intuitive Surgical 30 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, SYK or IDXX?

Stryker has higher revenue and earnings than IDEXX Laboratories. Stryker is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stryker $25.12B 5.07 $3.25B $8.64 38.46 IDEXX Laboratories $4.30B 10.11 $1.06B $13.58 40.61

Does the media prefer SYK or IDXX?

In the previous week, Stryker had 25 more articles in the media than IDEXX Laboratories. MarketBeat recorded 27 mentions for Stryker and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Stryker's score of 1.19 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stryker 21 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to IDXX or MDT?

In the previous week, Medtronic had 29 more articles in the media than IDEXX Laboratories. MarketBeat recorded 31 mentions for Medtronic and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Medtronic's score of 1.39 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Medtronic 23 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

IDEXX Laboratories (IDXX) Competitors

$551.50 -3.44 (-0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$547.00 -4.50 (-0.82%)

As of 07:57 PM Eastern

Compare

IDXX vs. NVST, ABT, ISRG, SYK, and MDT

Should you buy IDEXX Laboratories stock or one of its competitors? MarketBeat compares IDEXX Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IDEXX Laboratories include Envista (NVST), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT). These companies are all part of the "medical" sector.

How does IDEXX Laboratories compare to Envista?

Envista (NYSE:NVST) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

IDEXX Laboratories has a net margin of 24.63% compared to Envista's net margin of 2.41%. IDEXX Laboratories' return on equity of 70.87% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
IDEXX Laboratories	24.63%	70.87%	32.56%

87.8% of IDEXX Laboratories shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Envista presently has a consensus price target of $28.67, suggesting a potential upside of 6.29%. IDEXX Laboratories has a consensus price target of $751.00, suggesting a potential upside of 36.17%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe IDEXX Laboratories is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, IDEXX Laboratories had 2 more articles in the media than Envista. MarketBeat recorded 2 mentions for IDEXX Laboratories and 0 mentions for Envista. IDEXX Laboratories' average media sentiment score of 1.93 beat Envista's score of 0.89 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
Envista	Positive
IDEXX Laboratories	Very Positive

Envista has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

IDEXX Laboratories has higher revenue and earnings than Envista. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.61	$47M	$0.41	65.78
IDEXX Laboratories	$4.30B	10.11	$1.06B	$13.58	40.61

Summary

IDEXX Laboratories beats Envista on 14 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Abbott Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

IDEXX Laboratories has a net margin of 24.63% compared to Abbott Laboratories' net margin of 13.90%. IDEXX Laboratories' return on equity of 70.87% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Abbott Laboratories	13.90%	17.62%	10.01%

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IDEXX Laboratories has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

In the previous week, Abbott Laboratories had 47 more articles in the media than IDEXX Laboratories. MarketBeat recorded 49 mentions for Abbott Laboratories and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Abbott Laboratories' score of 1.10 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Abbott Laboratories	35 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Abbott Laboratories has higher revenue and earnings than IDEXX Laboratories. Abbott Laboratories is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	10.11	$1.06B	$13.58	40.61
Abbott Laboratories	$44.33B	3.69	$6.52B	$3.57	26.34

IDEXX Laboratories currently has a consensus target price of $751.00, suggesting a potential upside of 36.17%. Abbott Laboratories has a consensus target price of $118.30, suggesting a potential upside of 25.83%. Given IDEXX Laboratories' higher possible upside, equities research analysts clearly believe IDEXX Laboratories is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Abbott Laboratories	1 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.85

Summary

IDEXX Laboratories beats Abbott Laboratories on 11 of the 17 factors compared between the two stocks.

How does IDEXX Laboratories compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Intuitive Surgical presently has a consensus price target of $573.42, suggesting a potential upside of 41.69%. IDEXX Laboratories has a consensus price target of $751.00, suggesting a potential upside of 36.17%. Given Intuitive Surgical's stronger consensus rating and higher probable upside, research analysts plainly believe Intuitive Surgical is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.67
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Intuitive Surgical has a net margin of 28.15% compared to IDEXX Laboratories' net margin of 24.63%. IDEXX Laboratories' return on equity of 70.87% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
IDEXX Laboratories	24.63%	70.87%	32.56%

In the previous week, Intuitive Surgical had 39 more articles in the media than IDEXX Laboratories. MarketBeat recorded 41 mentions for Intuitive Surgical and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Intuitive Surgical's score of 1.32 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	30 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Intuitive Surgical has higher revenue and earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.58B	13.54	$2.86B	$8.25	49.05
IDEXX Laboratories	$4.30B	10.11	$1.06B	$13.58	40.61

Intuitive Surgical has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Summary

Intuitive Surgical beats IDEXX Laboratories on 9 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Stryker?

Stryker (NYSE:SYK) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Stryker has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Stryker has higher revenue and earnings than IDEXX Laboratories. Stryker is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$25.12B	5.07	$3.25B	$8.64	38.46
IDEXX Laboratories	$4.30B	10.11	$1.06B	$13.58	40.61

77.1% of Stryker shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IDEXX Laboratories has a net margin of 24.63% compared to Stryker's net margin of 13.20%. IDEXX Laboratories' return on equity of 70.87% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	13.20%	23.42%	11.04%
IDEXX Laboratories	24.63%	70.87%	32.56%

Stryker presently has a consensus target price of $395.33, suggesting a potential upside of 18.97%. IDEXX Laboratories has a consensus target price of $751.00, suggesting a potential upside of 36.17%. Given IDEXX Laboratories' higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Stryker had 25 more articles in the media than IDEXX Laboratories. MarketBeat recorded 27 mentions for Stryker and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Stryker's score of 1.19 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	21 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

IDEXX Laboratories beats Stryker on 10 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Medtronic?

IDEXX Laboratories (NASDAQ:IDXX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Medtronic has higher revenue and earnings than IDEXX Laboratories. Medtronic is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	10.11	$1.06B	$13.58	40.61
Medtronic	$36.36B	2.85	$4.80B	$3.73	21.70

IDEXX Laboratories currently has a consensus target price of $751.00, indicating a potential upside of 36.17%. Medtronic has a consensus target price of $99.00, indicating a potential upside of 22.32%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, research analysts plainly believe IDEXX Laboratories is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Medtronic	0 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.61

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by insiders. Comparatively, 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IDEXX Laboratories has a net margin of 24.63% compared to Medtronic's net margin of 13.20%. IDEXX Laboratories' return on equity of 70.87% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Medtronic	13.20%	14.51%	7.76%

In the previous week, Medtronic had 29 more articles in the media than IDEXX Laboratories. MarketBeat recorded 31 mentions for Medtronic and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.93 beat Medtronic's score of 1.39 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Medtronic	23 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Summary

IDEXX Laboratories beats Medtronic on 12 of the 16 factors compared between the two stocks.

Get IDEXX Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDXX vs. The Competition

Export

Metric	IDEXX Laboratories	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$43.78B	$7.35B	$6.71B	$12.23B
Dividend Yield	N/A	1.26%	2.67%	6.10%
P/E Ratio	40.61	51.24	26.03	24.18
Price / Sales	10.11	81.73	556.43	100.98
Price / Cash	36.78	25.94	46.99	54.37
Price / Book	27.44	7.56	10.77	6.35
Net Income	$1.06B	$159.20M	$3.57B	$337.63M
7 Day Performance	-1.88%	1.81%	3.15%	-0.30%
1 Month Performance	-1.02%	0.52%	2.33%	0.36%
1 Year Performance	4.49%	5.89%	33.42%	26.94%

IDEXX Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDXX IDEXX Laboratories	4.1106 of 5 stars	$551.50 -0.6%	$751.00 +36.2%	+4.6%	$43.78B	$4.30B	40.61	11,000	Positive News Analyst Upgrade High Trading Volume
NVST Envista	2.0956 of 5 stars	$24.68 +0.3%	$28.67 +16.2%	+37.3%	$4.00B	$2.72B	60.19	12,000
ABT Abbott Laboratories	4.9881 of 5 stars	$88.76 +0.7%	$118.38 +33.4%	-32.3%	$153.59B	$44.33B	24.86	115,000	Positive News
ISRG Intuitive Surgical	4.4758 of 5 stars	$416.55 +1.3%	$571.28 +37.1%	-23.4%	$145.58B	$10.06B	50.49	17,021	Positive News
SYK Stryker	4.9075 of 5 stars	$307.86 -1.4%	$395.33 +28.4%	-19.4%	$119.69B	$25.12B	35.63	56,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDXX) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEXX Laboratories (IDXX) Competitors

IDXX vs. NVST, ABT, ISRG, SYK, and MDT

How does IDEXX Laboratories compare to Envista?

Summary

How does IDEXX Laboratories compare to Abbott Laboratories?

Summary

How does IDEXX Laboratories compare to Intuitive Surgical?

Summary

How does IDEXX Laboratories compare to Stryker?

Summary

How does IDEXX Laboratories compare to Medtronic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX vs. The Competition

IDEXX Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEXX Laboratories (IDXX) Competitors

IDXX vs. NVST, ABT, ISRG, SYK, and MDT

How does IDEXX Laboratories compare to Envista?

Is NVST or IDXX more profitable?

Do insiders and institutionals have more ownership in NVST or IDXX?

Do analysts prefer NVST or IDXX?

Does the media favor NVST or IDXX?

Which has more risk & volatility, NVST or IDXX?

Which has better earnings and valuation, NVST or IDXX?

Summary

How does IDEXX Laboratories compare to Abbott Laboratories?

Is IDXX or ABT more profitable?

Do insiders & institutionals have more ownership in IDXX or ABT?

Which has more volatility & risk, IDXX or ABT?

Does the media prefer IDXX or ABT?

Which has better earnings and valuation, IDXX or ABT?

Do analysts rate IDXX or ABT?

Summary

How does IDEXX Laboratories compare to Intuitive Surgical?

Do analysts rate ISRG or IDXX?

Do insiders and institutionals have more ownership in ISRG or IDXX?

Is ISRG or IDXX more profitable?

Does the media prefer ISRG or IDXX?

Which has higher earnings & valuation, ISRG or IDXX?

Which has more volatility and risk, ISRG or IDXX?

Summary

How does IDEXX Laboratories compare to Stryker?

Which has more risk & volatility, SYK or IDXX?

Which has preferable valuation & earnings, SYK or IDXX?

Do institutionals & insiders have more ownership in SYK or IDXX?

Is SYK or IDXX more profitable?

Do analysts rate SYK or IDXX?

Does the media prefer SYK or IDXX?

Summary

How does IDEXX Laboratories compare to Medtronic?

Which has higher valuation & earnings, IDXX or MDT?

Do analysts rate IDXX or MDT?

Do institutionals and insiders believe in IDXX or MDT?

Is IDXX or MDT more profitable?

Does the media refer more to IDXX or MDT?

Which has more risk and volatility, IDXX or MDT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX vs. The Competition

IDEXX Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools